Bentley Systems Announces Seequent’s Acquisition of Minalytix
14.9.2021 23:01:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Seequent business unit has acquired Canadian software company Minalytix, the developer of MX Deposit. The acquisition extends Seequent’s cloud capabilities and solutions for mining, including greenfield exploration, resource development, and mining production. Prior to the transaction, Seequent held a minority shareholding in Minalytix, and its partnership included exclusive global rights to sell MX Deposit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914006105/en/
Seequent already integrates its Leapfrog, Oasis montaj, Target, and Imago solutions with MX Deposit, streamlining processes and increasing efficiency for geologists, engineers, and other stakeholders. For example, users can easily pull data captured in MX Deposit into Target to generate sections or Leapfrog Geo for 3D modeling and analysis of drill hole data. Teams can collaborate on models with Seequent Central and share with stakeholders using Leapfrog Viewer. (Photo: Business Wire)
MX Deposit simplifies and controls how drill hole and other field data is collected, managed, and shared throughout the lifecycle of a deposit. Mining exploration teams can configure the solution for various activities, including diamond and percussive drilling, grade control, underground face sampling, metallurgical sampling, stockpile sampling, and sampling mill circuits. MX Deposit closes gaps in a project’s data collection, streamlines workflow, reduces errors, and provides an audit trail to improve data confidence and act as a single source of truth for project data. MX Deposit is easy to use and configure and works anywhere online and offline, delivering valuable insights across all mining projects. Real-time collaboration is enabled with live project data.
Mining companies use MX Deposit, in conjunction with other geophysics and geology data management and modeling tools, to find, develop, and manage world-class deposits, and to enable teams to manage risk and make better, more profitable decisions. Data can be easily integrated into MX Deposit in order to provide context that delivers more knowledge and better decision making. Seequent already integrates its Leapfrog, Oasis montaj, Target, and Imago solutions with MX Deposit, streamlining processes and increasing efficiency for geologists, engineers, and other stakeholders. MX Deposit unlocks value from drilling, one of the largest investments for any mining and exploration company, with enduring high-quality data.
MX Deposit is an affordable Software-as-a-Service (SaaS) solution and auto-scales to meet users’ needs, from small to multi-national companies. Users can create a customized data management solution within hours, not days, to collect and control drill hole and other field data and immediately gain insights across all projects. There are no limits on data users can store, with some logging millions of samples and blast holes and tens of thousands of drill holes.
Graham Grant, chief executive officer of Seequent, said, “We’re excited to welcome the Minalytix team to Seequent, following our successful collaboration, to broaden the mining workflow through further cloud capabilities. Drill and sample data are the lifeblood for mining companies when exploring, and MX Deposit naturally aligns with our mining and exploration portfolio, including newly acquired geoscientific imagery platform Imago. We have already done a great job of integrating the software and now we are excited to integrate the team.”
Minalytix Co-founder and CEO David Peres said, “We’re delighted to join Seequent as it allows us to deliver on our founding mission to impact the mining industry positively. We partnered exclusively with Seequent a couple of years ago as they had earned a reputation as a trusted mining innovator with a global reach. As a result, demand for MX Deposit increased in leaps and bounds. With Seequent’s expertise and support, MX Deposit will be able to reach its full potential.”
For more information, please visit https://www.mxdeposit.net/
Caption: Seequent already integrates its Leapfrog, Oasis montaj, Target, and Imago solutions with MX Deposit, streamlining processes and increasing efficiency for geologists, engineers, and other stakeholders. For example, users can easily pull data captured in MX Deposit into Target to generate sections or Leapfrog Geo for 3D modeling and analysis of drill hole data. Teams can collaborate on models with Seequent Central and share with stakeholders using Leapfrog Viewer.
Caption: MX Deposit harnesses the collective power of a team to unlock value from drilling and sampling data. Users can build in important data validation rules into the system and collect quality data that will stand the test of time. A real-time activity feed allows team members to post comments and questions globally or to a specific group of people. In addition, users can tag images and comments to particular drill holes, samples, tables, records or values within a record. As a result, a complete audit trail is captured on every piece of data.
Caption: MX Deposit closes gaps in a project’s data collection from sample collection to lab analysis, ensuring company-wide consistency. Users can import assay results from a laptop in the office and even when off the grid in remote areas can grab samples with native Android and iOS applications that enable work fully offline. Data is automatically synced to the web application once users are back online.
##
About Seequent
Seequent, a Bentley company, is a world leader in the development of powerful geoscience analysis, modeling, and collaborative technologies for understanding geoscience and engineering design solutions. Our solutions enable people to analyze complex data, manage risk, and ultimately make better decisions about earth, environment, and energy challenges.
Seequent software is used on large-scale projects globally, including road and rail tunnel construction, groundwater detection and management, geothermal exploration, subsea infrastructure mapping, resource evaluation, and subterranean storage of spent nuclear fuel.
Seequent’s global footprint includes its Christchurch-based HQ and R&D centers in Christchurch and Canada with a network of offices across Asia/Pacific, Africa, South America, North America, and Europe, servicing organizations with leading subsurface solutions in over 100 countries. For more information, please visit www.seequent.com or follow Seequent on LinkedIn or Twitter.
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
www.bentley.com
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, Imago, iTwin, Leapfrog, Leapfrog Geo, MicroStation, Minalytix, MX Deposit, Oasis montaj, ProjectWise, Seequent, the Seequent logo, and Target are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914006105/en/
Contact information
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
